Oncology

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

With a 90% clinical trial failure rate, BullFrog AI is launching a new tool to help drugmakers make smarter, risk-balanced R&D decisions.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

A new AI-driven approach to cancer therapy promises to breach the blood-brain barrier, offering hope for treating aggressive tumors where others have failed.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

A major multi-vendor study confirms AI's power for precision HER2 scoring, promising to improve diagnostics and accelerate personalized cancer therapies.

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

A breakthrough in cancer therapy as Avacta's faridoxorubicin proves so safe, regulators have removed historic dosing limits tied to heart toxicity.

A new AI-powered blood test from CareDx shows promise in detecting cancer relapse weeks earlier, offering new hope for transplant patients.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A new report reveals a major shift in hospital spending, with tech and infrastructure costs now rising faster than drugs for the first time in a decade.

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

Beyond M&A, ACROBiosystems' bioSeedin summit redefines growth, connecting global capital with biotech innovation in a new era of strategic partnerships.

A new collaboration adapts world-class cancer treatment standards for Vietnam, offering new hope for women battling breast and ovarian cancer.

Ensem Therapeutics expands its global trial for ETX-636, a next-gen cancer drug designed to avoid common toxicities, into China's vast patient market.

A new platform, Accelerated Clinical Trials (ACT), promises to slash drug development timelines by up to 20 months, but faces regulatory and ethical hurdles.

With a major cash infusion, NeOnc Technologies is set to accelerate its promising therapies aimed at conquering the elusive blood-brain barrier.

With backing from a top hospital, VolitionRx seeks reimbursement for its Nu.Q® blood test, aiming to transform lung cancer care in France and beyond.